Pharmacological and physicochemical factors in the pressor effects of conjugated haemoglobin-based oxygen carriers in vivo

Journal of Hypertension

Volumn 25, Issue 3, 2007, Pages 599-608

  Smani, Younes ^a,b   Fifre, Alexandre ^a   Labrude, Pierre ^a   Vigneron, Claude ^a   Faivre, Béatrice ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b NONE   (France)

Author keywords

Endothelin; Endothelin receptor type B; Haemoglobin based oxygen carriers; Hypertension; Reactive oxygen species

Indexed keywords

CONJUGATED HAEMOGLOBIN BASED OXYGEN CARRIER; ENDOTHELIN; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; HEMOGLOBIN; METHEMOGLOBIN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; OXYGEN; OXYHEMOGLOBIN; PROTEIN DERIVATIVE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOOXIDATION; BLOOD VESSEL; BLOOD VESSEL WALL; CONTROLLED STUDY; CORRELATION ANALYSIS; EXCHANGE BLOOD TRANSFUSION; GUINEA PIG; HEMODYNAMICS; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXYGEN BLOOD LEVEL; OXYGEN CONCENTRATION; PHYSICAL CHEMISTRY; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN SECRETION; VASOCONSTRICTION; WESTERN BLOTTING;

EID: 33846849275     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3280119000     Document Type: Article

References (49)

1. Kjellström BT. Blood substitutes: where do we stand today? J Intern Med 2003; 253:495-497.
2. Vandegriff KD. Haemoglobin-based oxygen carriers. Expert Opin Investig Drugs 2000; 9:1967-1984.
3. Chang TMS. Future generations of red blood cell substitutes. J Intern Med 2003; 253:527-535.
4. Nakai K, Ohta T, Sakuma I, Akama K, Kobayashi Y, Tokuyama S, et al. Inhibition of endothelium-dependent relaxation by hemoglobin in rabbit aortic strips: comparison between acellular hemoglobin derivatives and cellular hemoglobins. J Cardiovasc Physiol 1996; 28:115-123.
5. Doherty DH, Doyle MP, Curry SR, Vali RJ, Fattor TJ, Olsen JS, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 1998; 16:672-676.
6. Rohlfs RJ, Bruner E, Chiu A, Gonzales A, Gonzales ML, Magde D, et al. Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. J Biol Chem 1998; 273:12128-12134.
7. Fitzpatrick CM, Savage SA, Kerby JD, Clouse WD, Kashyap VS. Resuscitation with a blood substitute causes vasoconstriction without nitric oxide scavenging in a model of arterial hemorrhage. J Am Coll Surg 2004; 199:693-701.
8. Alayash AI. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants? Nat Biotechnol 1999; 17:545-549.
9. Darley-Usmar VM, Radomski R. Free radicals in the vasculature - the good, the bad, and the ugly. Biochemist 1994; 16:15-18.
10. Motterlini R, Foresti R, Vandegriff KD, Intagliatta M, Winslow RW. Oxidative stress response in vascular endothelial cells exposed to acellular hemoglobin solution. Am J Physiol 1995; 269:H648-H655.
11. Alayash AI, Cashon RE. Hemoglobin and free radicals, implications for the development of a safe blood substitute. Mol Med Today 1995; 1:122-127.
12. Winterboun CC. Oxidative reactions of hemoglobin. Methods Enzymol 1990; 186:265-272.
13. Stowell CP, Levin J, Spiess BD, Winslow RM. Progress in the development of RBC substitutes. Transfusion 2001; 41:287-299.
14. Vanhoutte PM, Rubanyi GM, Miller VM, Houston DS. Modulation of vascular smooth muscle contraction by the endothelium. Ann Rev Physiol 1986; 48:307-320.
15. Palombo JD, Blackburn GL, Forse RA. Endothelial cell factors and response to injury. Surg Gynecol Obstet 1991; 173:505-518.
16. Rubanyi GM. Endothelium-derived relaxing and contracting factors. J Cell Biochem 1991; 46:27-36.
17. Angulo J, Sanchez-Ferrer CF, Peiró C, Marin J, Rodriguez-Mañas L. Impairment of endothelium-dependent relaxations by increasing percentages of glycosylated human hemoglobin. Possible mechanisms involved. Hypertension 1996; 28:583-592.
18. Diederich D, Skopec J, Diederich A, Dai FX. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 1994; 23:957-961.
19. .- formation. Nephrol Dial Transplant 2000; 15:339-346.
20. King AJ. Endothelins: multifunctional peptides with potent vasoactive properties. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management, 2nd ed. New York: Raven Press; 1991. pp. 631-672.
21. Clozel M, Breu V. The role of ETB receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ETB receptor antagonist RO 46-8443. FEBS Lett 1996; 383:42-45.
22. Mortensen LH, Pawloski CM, Kanagy NL, Fink GD. Chronic hypertension produced by infusion of endothelin in rats. Hypertension 1990; 15:729-733.
23. Wilkins FC Jr, Alberola A, Mizelle HL, Opgenorth TJ, Granger JP. Systemic hemodynamics and renal function during long-term pathophysiological increases in circulating endothelin. Am J Physiol 1995; 268:375-381.
24. Cocks TM, Malta E, King SJ, Woods RL, Angus JA. Oxyhaemoglobin increases the production of endothelin-1 by endothelial cells in culture. Eur J Pharmacol 1991; 196:177-182.
25. Schultz SC, Grady B, Cole F, Hamilton I, Burhop K, Malcolm DS. A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J Lab Clin Med 1993; 122:301-308.
26. Gulati A, Sen AP, Sharma AC, Singh G. Role of ET and NO in resuscitative effect of diaspirin cross-linked hemoglobin after hemorrhage in rat. Am J Physiol 1997; 273:H827-H836.
27. Lin G, Macdonald RL, Marton LS, Kowalczuk A, Solenski NJ, Weir BK. Hemoglobin increases endothelin-1 in endothelial cells by decreasing nitric oxide. Biochem Biophys Res Commun 2001; 280:824-830.
28. Caron A, Menu P, Faivre-Fiorina B, Labrude P, Alayash AI, Vigneron C. Cardiovascular and hemorheological effects of three modified human hemoglobin solutions in hemodiluted rabbits. J Appl Physiol 1999; 86:541-548.
29. Prouchayret F, Fasan G, Grandgeorge M, Vigneron C, Menu P, Dellacherie E. In: Chang TMS, editor. Blood substitutes and oxygen carriers. New York: Dekker; 1993. pp. 144-147.
30. Smani Y, Faivre B, Audonnet-Blaise S, Labrude P, Vigneron C. Hemoglobin-based oxygen carrier distribution inside vascular wall and arterial pressure evolution: is there a relationship? Eur Surg Res 2005; 37:1-8.
31. Crapo JD, McCord JM, Fridovich I. Preparation and assay of superoxide dismutases. Methods Enzymol 1978; 53:382-393.
32. Jia Y, Wood F, Menu P, Faivre B, Caron A, Alayash AI. Oxygen binding and oxidation reactions of human hemoglobin conjugated to carboxylate dextran. Biochim Biophys Acta 2004; 1672:164-173.
33. Caron A, Menu P, Labrude P, Vigneron C. Proposition of a technique to assess the vasoactive effects of hemoglobin-based oxygen carrying solutions in vivo: preliminary results in the rabbit aorta. Artif Cells Blood Substit Immobil Biotechnol 1998; 26:293-308.
34. Caron A, Menu P, Faivre-Fiorina B, Labrude P, Vigneron C. The effects of stroma-free and dextran-conjugated hemoglobin on hemodynamics and carotid blood flow in hemorrhaged guinea pigs. Artif Cells Blood Substit Immobil Biotechnol 1999; 27:49-64.
35. Zhao SP, Cai HW, Liu ZS, Yang HW, Yang Y. Intraoperative application of acute normovolemic hemodilution. Hunan Yi Ke Da Xue Xue Bao 2000; 25:83-84.
36. Macdonald VW. Methemoglobin-induced decrease of vascular reactivity to stroma-free hemoglobin in isolated perfused rabbit hearts. Prog Clin Biol Res 1989; 319:423-433; discussion 434.
37. Buehler PW, Alayash AI. Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems. Transfusion 2004; 44:1516-1530.
38. Sutton HC, Roberts PB, Winterboun CC. The rate of reaction of superoxide radical ion with oxyhaemoglobin and methaemoglobin. Biochem J 1976; 155:503-510.
39. Alayash AI. Oxygen therapeutics: can we tame haemoglobin? Nat Rev 2004; 3:152-159.
40. Pollock DM, Pollock JS. Endothelin and oxidative stress in the vascular system. Curr Vasc Pharmacol 2005; 3:365-367.
41. Kähler J, Mendel S, Weckmüller J, Orzechowski HD, Mittmann C, Köster R, et al. Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol 2000; 32:1429-1437.
42. De Artiñano AA, Gonzalez VLP. Endothelial dysfunction and hypertensive vasoconstriction. Pharmacol Res 1999; 40:113-124.
43. Love GP, Miller K, Keenan AK. Reduced endothelin-1 secretion by pulmonary vascular endothelial-cells exposed to hypoxanthine-xanthine oxidase [abstract]. Br J Pharmacol 1995; 116:428.
44. Wang X, Tong M, Chinta S, Raj JU, Gao Y. Hypoxia-induced reactive oxygen species downregulate ET B receptor-mediated contraction of rat pulmonary arteries. Am J Physiol Lung Cell Moll Physiol 2006; 290:L570-L578.
45. Freedman NJ, Ament AS, Oppermann M, Stoffel RH, Exum ST, Lefkowitz RJ. Phosphorylation and desensitization of human endothelin A and B receptors. Evidence for G protein-coupled receptor kinase specificity. J Biol Chem 1997; 272:17734-17743.
46. Oksche A, Boese G, Horstmeyer A, Furkert J, Beyermann M, Bienert M, et al. Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Moll Pharmacol 2000; 57:1104-1113.
47. Vuylsteke A, Davidson HJ, Ho WSV, Ritchie AJ, Callingham BA, White R, et al. Effect of the blood substitute diaspirin crosslinked hemoglobin in rat mesenteric and human radial collateral arteries. J Cardiovasc Pharmacol 2001; 37:394-405.
48. Tai J, Kim HW, Greenburg AG. Endothelin-1 is not involved in hemoglobins associated vasoactivities. Artif Cells Blood Substit Immobil Biotechnol 1997; 25:135-140.
49. Heller A, Ragaller M, Schmeck J, Fluth H, Muller M, Albrecht DM, et al. Role of NO and endothelin in hemoglobin-induced pulmonary vasoconstriction. Shock 1998; 10:401-406.